Human health and medicine

Ibritumomab tiuxetan

Ibritumomab tiuxetan (Zevalin) is a murine anti-CD20 antibody linked via tiuxetan to yttrium-90, the first FDA-approved radioconjugated antibody for cancer (2002), treating relapsed or refractory B-cell non-Hodgkin lymphoma; EU authorization lapsed in 2024.

Ibrutinib

Ibrutinib (Imbruvica) is the first-in-class oral covalent Bruton's tyrosine kinase inhibitor, binding C481 irreversibly. Approved by the FDA from November 2013 for CLL/SLL, Waldenström's macroglobulinemia, and cGVHD; MCL and MZL indications withdrawn in 2023.

Ibrutinib plus obinutuzumab

Ibrutinib plus obinutuzumab is a chemotherapy-free combination regimen pairing the oral BTK inhibitor ibrutinib with the anti-CD20 antibody obinutuzumab, FDA approved in 2019 for previously untreated chronic lymphocytic leukemia.

Ibrutinib regimen

The ibrutinib regimen is a combination treatment for primary central nervous system lymphoma in which the BTK inhibitor ibrutinib is given with high-dose methotrexate, usually with rituximab.

Ibrutinib–venetoclax regimen

The ibrutinib–venetoclax regimen is an all-oral, fixed-duration therapy pairing the BTK inhibitor ibrutinib with the BCL-2 inhibitor venetoclax, used mainly for chronic lymphocytic leukemia and authorized in Europe in 2022.

Ibudilast

Ibudilast (MN-166, AV411, Ketas) is an oral nonselective PDE inhibitor (PDE-3/4/10/11) also inhibiting MIF and TLR-4; approved in Japan since 1989 for asthma and post-stroke dizziness, in trials for progressive MS and ALS.

Ibufenac

Ibufenac (Dytransin, Boots), 4-isobutylphenylacetic acid, an NSAID anti-inflammatory analgesic marketed 1966 for rheumatic disease and withdrawn February 1968 for hepatotoxicity; predecessor of ibuprofen.

Ibuprofen

Ibuprofen (2-(4-isobutylphenyl) propionic acid; brands Brufen, Motrin, Nurofen, Advil) is an NSAID painkiller and fever reducer discovered by Stewart Adams and John Nicholson at Boots, patented 1961, launched 1969.

Ibutamoren

Ibutamoren (MK-677, MK-0677, LUM-201) is an oral non-peptide ghrelin receptor agonist that raises GH and IGF-1; synthesized by Merck in 1995, discontinued in 1999, never FDA approved, and WADA-prohibited since 2013.

Ibutilide

Ibutilide (ibutilide fumarate, Corvert) is an intravenous class III antiarrhythmic for acute cardioversion of atrial fibrillation and flutter, acting via I_Kr blockade and late sodium current activation, with torsades de pointes as its main risk.

Icchabhedi rasa

Icchabhedi rasa (Icchābhedi rasa), an Ayurvedic herbo-mineral tablet formulation (AFI000443, 250 mg dose) with mercury, sulphur, borax, black pepper, ginger, and croton seed, used as a purgative in virechana panchakarma therapy.

ICD classification of hypertensive heart disease

The ICD classification of hypertensive heart disease is ICD-10 category I11, split into I11.0 with heart failure and I11.9 without, replacing ICD-9 code 402 and mapping to ICD-11 code BA01.

ICD-10

ICD-10 is the WHO's Tenth Revision disease classification, adopted 1990, effective 1993; the US uses ICD-10-CM (diagnoses) and ICD-10-PCS (procedures) since October 1, 2015, with ICD-11 effective 2022.

ICD-11 classification of personality disorders

ICD-11 personality disorder classification (WHO, effective 2022): single dimensional diagnosis 6D10 rated mild, moderate, or severe, five trait domains (negative affectivity, detachment, dissociality, disinhibition, anankastia), optional borderline pattern specifier, replacing ICD-10's ten categorical diagnoses.

ICE chemotherapy regimen

The ICE chemotherapy regimen combines ifosfamide, carboplatin, and etoposide, used mainly as salvage treatment for relapsed or refractory Hodgkin and non-Hodgkin lymphoma, often before stem cell transplantation.

ICE trial (NCT05731973)

The ICE trial (NCT05731973) was a Dutch randomized trial comparing intercostal nerve cryoablation with thoracic epidural analgesia for pain control after the Nuss procedure for pectus excavatum.

ICF syndrome

ICF syndrome, or immunodeficiency, centromeric instability, and facial anomalies syndrome, is a rare autosomal recessive immunodeficiency first described in 1978, marked by low antibody levels, characteristic facial features, and instability of chromosomes 1 and 16.

ICHAD syndrome

ICHAD syndrome (Immunodysregulation, Craniofacial anomalies, Hearing impairment, Athelia, Developmental delay) is a rare autosomal dominant IKZF2 disorder from de novo dominant negative HELIOS zinc finger variants, causing immune dysregulation with developmental features.

Ichthyosis

Ichthyosis: a group of rare inherited or acquired skin disorders causing dry, scaly skin from defective epidermal barrier formation. Includes ichthyosis vulgaris, X-linked, ARCI, and harlequin forms; treated with emollients, keratolytics, and retinoids.

Ichthyosis follicularis-alopecia-photophobia syndrome

Ichthyosis follicularis-alopecia-photophobia (IFAP) syndrome is a rare genetic disorder characterized from birth by follicular ichthyosis, body-wide hair loss, and photophobia, primarily affecting males and caused by mutations in the X-linked MBTPS2 gene.

Ichthyosis hystrix of Curth-Macklin

Ichthyosis hystrix of Curth-Macklin (IHCM), also called ichthyosis Curth-Macklin, is an ultrarare autosomal dominant keratinopathic ichthyosis caused by KRT1 frameshift mutations, marked by spiky hyperkeratosis, mutilating palmoplantar keratoderma, and binucleated keratinocytes, without blistering.

Ichthyosis vulgaris

Ichthyosis vulgaris (fish scale disease), the most common inherited ichthyosis, is caused by FLG filaggrin gene mutations, affects about 1 in 250 people, and causes dry, scaly skin with atopic dermatitis in 50% of cases.

Ichthyosis-prematurity syndrome

Ichthyosis-prematurity syndrome (IPS, congenital ichthyosis type 4) is a rare autosomal recessive ichthyosis from SLC27A4 mutations, causing premature birth, clay-like vernix, neonatal asphyxia, eosinophilia, and later mild atopic follicular hyperkeratosis.

Iclaprim

Iclaprim (Ro 48-2622, AR-100) is an investigational 2,4-diaminopyrimidine dihydrofolate reductase inhibitor active against Gram-positive bacteria including MRSA and trimethoprim-resistant strains; not FDA or EMA approved.

Icodextrin

Icodextrin (Extraneal) is a starch-derived glucose polymer, average MW 16,000 D, used as a 7.5% colloid-osmotic agent for long-dwell peritoneal dialysis exchanges, first registered 1997, with maltose-based glucose meter interference as its key warning.

Icomidocholic acid

Icomidocholic acid (aramchol, arachidyl amido cholanoic acid, C20-FABAC) is Galmed's synthetic cholic acid–arachidic acid conjugate and partial SCD1 inhibitor in phase 3 (ARMOR) for MASH/NASH, not yet approved.

ICON1 study

ICON1 (NCT01933581) is a UK prospective observational cohort study of patients aged 75+ with non-ST-elevation acute coronary syndrome undergoing invasive care; it produced the FRAIL-HEART risk score, which outperformed GRACE 2.

ICONE trial

ICONE trial (NCT05699005), a French multicenter randomized trial from University Hospital, Lille, comparing individualized ScvO2-triggered versus conventional hemoglobin <9 g/dL red cell transfusion in adults on VA-ECMO for refractory cardiogenic shock; 236 patients, recruiting.

Icotinib

Icotinib (埃克替尼, Conmana, BPI-2009) is an oral first-generation EGFR tyrosine kinase inhibitor developed by Betta Pharmaceuticals, approved in China in 2011 for EGFR-mutant NSCLC, with pivotal trials ICOGEN, CONVINCE, BRAIN, and EVIDENCE.